Carla de Boer ▲ Sign in to save

• Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

  2024 The Lancet Oncology article Medicine Multiple Myeloma Research and Treatments Open access

  130

  citations
• Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

  2022 Haematologica article Medicine Multiple Myeloma Research and Treatments Open access

  26

  citations
• Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

  2021 Blood conference-abstract Medicine Multiple Myeloma Research and Treatments

  21

  citations
• Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

  2021 The Lancet Oncology article Medicine Multiple Myeloma Research and Treatments Open access

  182

  citations
• Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

  2021 Clinical Lymphoma Myeloma & Leukemia article Medicine Multiple Myeloma Research and Treatments

  12

  citations
• Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study

  2021 Haematologica article Medicine Multiple Myeloma Research and Treatments Open access

  54

  citations
• Front-Line Daratumumab-VTd Versus Standard-of-Care in ASCT-Eligible Multiple Myeloma: Matching-Adjusted Indirect Comparison

  2020 Immunotherapy article Medicine Multiple Myeloma Research and Treatments Open access

  18

  citations
• Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial

  2020 The Lancet Haematology article Medicine Multiple Myeloma Research and Treatments Open access cited by 1 patent

  36

  citations
• Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching

  2020 eJHaem article Medicine Multiple Myeloma Research and Treatments Open access

  6

  citations
• Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.

  2020 Journal of Clinical Oncology conference-abstract Medicine Multiple Myeloma Research and Treatments

  8

  citations
• Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

  2020 Blood article Medicine Multiple Myeloma Research and Treatments Open access

  703

  citations

11 results